Wire · regulatory
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
◆ Sectors
Medtech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 25 September 2026 · Fusion42 review
The FDA has approved Baricitinib for use in adolescents with severe alopecia areata, expanding treatment options for this patient group in the United States.
This Wire brief sits within Fusion42's coverage of Medtech, and 4 sources have reported it between 25 Sep 2026 and 29 Sep 2026.
◆ ◆ The Wire takeaway
The FDA's green light for Baricitinib in teens with severe alopecia opens a new US market for treatments targeting youth autoimmune hair loss. You can now explore partnerships or product lines aligned with this newly approved therapy's patient base.
◆ Coverage
4 sources · first reported 25 Sep 2026 · latest 29 Sep 2026
◆ Related on Wire
◆ Topics
Medtechfda-approvalbaricitinibalopecia-areataadolescentsmedtech